Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

A competing risk nomogram predicting cause-specific mortality in patients with lung adenosquamous carcinoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Cardiovascular disease in women with breast cancer - a nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Are cancer patients better off if they participate in clinical trials? A mixed methods study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Structured and evidence-based training of technical skills in respiratory medicine and thoracic surgery

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Efficacy and safety of omitting chest drains after video-assisted thoracoscopic surgery: a systematic review and meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Guidelines for enhanced recovery after lung surgery: need for re-analysis

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  4. Ten-Year Trends of Clinicopathologic Features and Surgical Treatment of Lung Cancer in China

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Xiao Wu
  • Wenfeng Yu
  • R H Petersen
  • Hongxu Sheng
  • Yiqing Wang
  • Wang Lv
  • Jian Hu
Vis graf over relationer

BACKGROUND: Adenosquamous carcinoma (ASC) is an uncommon histological subtype of lung cancer. The purpose of this study was to assess the cumulative incidences of lung cancer-specific mortality (LC-SM) and other cause-specific mortality (OCSM) in lung ASC patients, and construct a corresponding competing risk nomogram for LC-SM.

METHODS: Data on 2705 patients with first primary lung ASC histologically diagnosed between 2004 and 2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. The cumulative incidence function (CIF) was utilized to calculate the 3-year and 5-year probabilities of LC-SM and OCSM, and a competing risk model was built. Based on the model, we developed a competing risk nomogram to predict the 3-year and 5-year cumulative probabilities of LC-SM and the corresponding concordance indexes (C-indexes) and calibration curves were derived to assess the model performance. To evaluate the clinical usefulness of the nomogram, decision curve analysis (DCA) was conducted. Furthermore, patients were categorized into three groups according to the tertile values of the nomogram-based scores, and their survival differences were assessed using CIF curves.

RESULTS: The 3-year and 5-year cumulative mortalities were 49.6 and 55.8% for LC-SM and 8.2 and 11.8% for OCSM, respectively. In multivariate analysis, increasing age, male sex, no surgery, and advanced T, N and M stages were related to a significantly higher likelihood of LC-SM. The nomogram showed good calibration, and the 3-year and 5-year C-indexes for predicting the probabilities of LC-SM in the validation cohort were both 0.79, which were almost equal to those of the ten-fold cross validation. DCA demonstrated that using the nomogram gained more benefit when the threshold probabilities were set within the ranges of 0.24-0.89 and 0.25-0.91 for 3-year and 5-year LCSM, respectively. In both the training and validation cohorts, the high-risk group had the highest probabilities of LC-SM, followed by the medium-risk and low-risk groups (both P < 0.0001).

CONCLUSIONS: The competing risk nomogram displayed excellent discrimination and calibration for predicting LC-SM. With the aid of this individualized predictive tool, clinicians can more expediently devise appropriate treatment protocols and follow-up schedules.

TidsskriftBMC Cancer
Udgave nummer1
Sider (fra-til)429
StatusUdgivet - 16 maj 2020

ID: 62067896